Cat. No.: HY-126030

(+)-Syringaresinol

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC₅₀ of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia.

For research use only. We do not sell to patients.

Purity: 98.78%
CAS No.: 21453-69-0
Formula: C₂₂H₂₆O₈
Molecular Weight:418.44

Storage:

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

(+)-Syringaresinol Chemical Structure

CAS No.: 21453-69-0

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC₅₀ of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemia^[1]^[2].

IC₅₀ & Target

IC50: 329.4 μM (NFAT transcription factor)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	ED₅₀	13.92 μg/mL Compound: (+)-syringaresinol	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1453182]
A549	ED₅₀	14.9 μg/mL Compound: 7	Cytotoxicity against human A549 cells after 7 days Cytotoxicity against human A549 cells after 7 days	[PMID: 1593281]
A549	IC₅₀	>100 μM Compound: 42	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 18440233]
A549	IC₅₀	>20 μg/mL Compound: 13	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 23511021]
B16-BL6	IC₅₀	>100 μM Compound: 42	Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay	[PMID: 18440233]
HeLa	IC₅₀	>100 μM Compound: 42	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	[PMID: 18440233]
Hep 3B2	IC₅₀	15.73 μg/mL Compound: 13	Cytotoxicity against human Hep3B cells Cytotoxicity against human Hep3B cells	[PMID: 23511021]
HepG2	IC₅₀	>20 μg/mL Compound: 13	Cytotoxicity against human HepG2 cells Cytotoxicity against human HepG2 cells	[PMID: 23511021]
HT-1080	IC₅₀	>100 μM Compound: 42	Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 18440233]
HT-29	ED₅₀	15.5 μg/mL Compound: 7	Cytotoxicity against human HT-29 cells after 7 days Cytotoxicity against human HT-29 cells after 7 days	[PMID: 1593281]
KB	IC₅₀	>47.8 μM Compound: 10	Cytotoxicity against human KB cells by sulforhodamine B assay Cytotoxicity against human KB cells by sulforhodamine B assay	[PMID: 26928423]
Lewis lung carcinoma cell line	IC₅₀	>100 μM Compound: 42	Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay	[PMID: 18440233]
MCF7	ED₅₀	30.31 μg/mL Compound: (+)-syringaresinol	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1453182]
MCF7	ED₅₀	3.69 μg/mL Compound: 7	Cytotoxicity against human MCF7 cells after 7 days Cytotoxicity against human MCF7 cells after 7 days	[PMID: 1593281]
MCF7	IC₅₀	>20 μg/mL Compound: 13	Cytotoxicity against human MCF7 cells Cytotoxicity against human MCF7 cells	[PMID: 23511021]
MDA-MB-231	IC₅₀	>20 μg/mL Compound: 13	Cytotoxicity against human MDA-MB-231 cells Cytotoxicity against human MDA-MB-231 cells	[PMID: 23511021]
N9	IC₅₀	2.68 μM Compound: 16	Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 28073678]
P388	ED₅₀	0.56 μg/mL Compound: (+/-)-Syringaresinol	Cytotoxicity against mouse P388 cells Cytotoxicity against mouse P388 cells	[PMID: 3783168]
PANC-1	IC₅₀	61.1 μM Compound: 6	Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay Cytotoxicity against human PANC1 cells after 72 hrs by WST8 assay	[PMID: 28495081]
RAW264.7	IC₅₀	0.047 mM Compound: 8	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
RAW264.7	IC₅₀	0.047 μM/mL Compound: 8	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs	[PMID: 18986199]
RAW264.7	IC₅₀	14.8 μM Compound: 15	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method	[PMID: 21435874]
RAW264.7	IC₅₀	>50 μM Compound: 6	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25592708]
RAW264.7	IC₅₀	21.6 μM Compound: 15	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
RAW264.7	IC₅₀	>50 μM Compound: 18	Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay Antiinflammatory activity in mouse RAW264.7 assessed as inhibition of LPS-induced NO production preincubated for 30 mins followed by LPS stimulation measured after 24 hrs by Griess reagent based assay	[PMID: 33939429]
Vero	IC₅₀	>47.8 μM Compound: 10	Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay Cytotoxicity against African green monkey Vero cells by sulforhodamine B assay	[PMID: 26928423]

In Vitro

(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED₅₀ 0.41 μg/mL^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 21453-69-0
Appearance Solid
Molecular Weight 418.44
Formula C₂₂H₂₆O₈
Color White to off-white
SMILES

OC1=C(C=C(C=C1OC)[C@@H]2[C@@]3([C@]([H])(CO2)[C@H](OC3)C4=CC(OC)=C(C(OC)=C4)O)[H])OC
Structure Classification
- Phenylpropanoids
- Lignans
- Phenols
- Polyphenols
Initial Source
- Plants
- Compositae
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

-20°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (1)

All

Sort by:

Journal Impact Factor

Pak J Pharm Sci

Syringaresinol inhibits ferroptosis and ameliorates glucocorticoid-induced MC3T3-E1 osteoporosis by modulating the Nrf2/SLC7A11/GPX4 pathway. [Abstract]

2026 Jan;39(1):102-116. PMID: 41482780

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (59.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3898 mL

11.9491 mL

23.8983 mL

5 mM

0.4780 mL

2.3898 mL

4.7797 mL

10 mM

0.2390 mL

1.1949 mL

2.3898 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Cai XF, et, al. Inhibitory lignans against NFAT transcription factor from Acanthopanax koreanum. Arch Pharm Res. 2004 Jul;27(7):738-41. [Content Brief]

[2]. Badawi MM, et, al. Plant anticancer agents XXVII: Antileukemic and cytotoxic constituents of Dirca occidentalis (Thymelaeaceae). J Pharm Sci. 1983 Nov;72(11):1285-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3898 mL	11.9491 mL	23.8983 mL	59.7457 mL
	5 mM	0.4780 mL	2.3898 mL	4.7797 mL	11.9491 mL
	10 mM	0.2390 mL	1.1949 mL	2.3898 mL	5.9746 mL
	15 mM	0.1593 mL	0.7966 mL	1.5932 mL	3.9830 mL
	20 mM	0.1195 mL	0.5975 mL	1.1949 mL	2.9873 mL
	25 mM	0.0956 mL	0.4780 mL	0.9559 mL	2.3898 mL
	30 mM	0.0797 mL	0.3983 mL	0.7966 mL	1.9915 mL
	40 mM	0.0597 mL	0.2987 mL	0.5975 mL	1.4936 mL
	50 mM	0.0478 mL	0.2390 mL	0.4780 mL	1.1949 mL

Keywords

(+)-Syringaresinol

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

(+)-Syringaresinol

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) (+)-Syringaresinol

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(+)-Syringaresinol

MCE Bioactive Compound Library

Natural Product Library Plus

Publications Citing Use of MedChemExpress (MCE) (+)-Syringaresinol

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

(+)-Syringaresinol Related Classifications

HY-126030 Related Classifications